印度推出10 000 克罗尔生物药厂Shakti计划,以促进生物工程的制造和自力更生。 India launches ₹10,000 crore Biopharma Shakti plan to boost biologics manufacturing and self-reliance.

财政部长Nirmala Sitharaman在2026-27年的联邦预算中宣布了一项为期5年的生物制药Shakti倡议, Finance Minister Nirmala Sitharaman announced a ₹10,000 crore, five-year Biopharma Shakti initiative in the 2026-27 Union Budget to boost India’s biopharmaceutical sector, focusing on biologics, biosimilars, and advanced therapies for chronic diseases. 该计划包括设立三个新的国家药物教育和研究所,更新现有的七个研究所,建立1 000多个经认可的临床试验场所,并通过CDSCO加强监管监督。 The plan includes establishing three new National Institutes of Pharmaceutical Education and Research, upgrading seven existing ones, creating over 1,000 accredited clinical trial sites, and strengthening regulatory oversight through the CDSCO. 补充措施支持半导体制造,支持Odisha、Kerala、Andhra Pradesh和泰米尔纳德邦的关键矿产开发,扩大医疗电子和纺织品基础设施。 Additional measures support semiconductor manufacturing, critical mineral development in Odisha, Kerala, Andhra Pradesh, and Tamil Nadu, and expanded infrastructure for medical electronics and textiles. 预算强调战略部门之间的包容性增长、创新和自力更生。 The budget emphasizes inclusive growth, innovation, and self-reliance across strategic sectors.